US-list­ed Chi­nese biotechs dodge threat of delist­ing

US-list­ed Chi­nese com­pa­nies can ex­hale, as the US’ Pub­lic Com­pa­ny Ac­count­ing Over­sight Board (PCAOB) an­nounced on Thurs­day that it was able to in­spect the au­dit re­ports of a long list of firms that were un­der threat of delist­ing.

Months ago, rough­ly 200 busi­ness­es — in­clud­ing BeiGene, Hutchmed, Zai Lab, I-Mab, Sino­vac, Gra­cell Biotech­nolo­gies, Ada­gene and Burn­ing Rock Biotech — had been sin­gled out by the SEC for vi­o­lat­ing a new law gov­ern­ing US-list­ed com­pa­nies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER